文献速递哮喘

韩国成人哮喘早期临床缓解与肺功能下降及急性发作的关系

Early clinical remission and its role in lung function decline and exacerbation in adult Korean patients with asthma.
PubMed 文献 · Thorax · 2025-04-15

该回顾性队列研究纳入492例接受吸入性糖皮质激素治疗的哮喘患者,评估起始治疗后1年内达到早期临床缓解对肺功能下降和急性发作风险的影响。结果显示早期4项标准缓解与较慢的年FEV1下降及中重度、重度急性发作风险降低显著相关。

要点

  • 早期4项标准临床缓解与年FEV1下降减缓显著相关(调整β=31.6 mL/年,p=0.001)。
  • 早期4项标准临床缓解与中重度急性发作风险降低相关(aHR=0.591,p=0.011)。
  • 早期4项标准临床缓解与重度急性发作风险降低相关(aHR=0.508,p=0.025)。

核心结论

  • 在ICS起始治疗1年内达到临床缓解与更好的肺功能保留和更低的急性发作风险相关。

研究设计与样本

  • 回顾性队列研究,纳入两所教学医院492例接受ICS治疗的哮喘患者,分为早期临床缓解组和非早期临床缓解组。

主要发现

  • 早期4项标准临床缓解与较慢的年FEV1下降显著相关(调整β=31.6 mL/年,p=0.001),3项标准缓解亦相关(调整β=15.7 mL/年,p=0.043)。
  • 早期4项标准临床缓解对减缓年FEV1下降的益处在于2型高表达哮喘、持续性气流受限、重症哮喘及需加用长效抗胆碱能药物患者中更明显。
  • 早期4项标准临床缓解与中重度急性发作风险降低相关(aHR=0.591,p=0.011),与重度急性发作风险降低相关(aHR=0.508,p=0.025)。

关键数值与推荐

  • 早期临床缓解定义为ICS起始后第一年内持续无急性发作、未使用全身性糖皮质激素、症状控制且肺功能稳定或改善的综合标准。

临床怎么用

  • 可将早期临床缓解作为哮喘管理的临床目标,以期改善肺功能保留并降低急性发作风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Despite advancements in asthma management, many patients continue to experience poor disease control, lung function decline, and frequent exacerbations. Clinical remission (CR) has been proposed as a novel treatment target and surrogate marker for long-term outcomes. This study evaluates whether early CR at 1 year after inhaled corticosteroid (ICS) initiation influences lung function decline and exacerbation risk in asthma. METHODS: This retrospective cohort study evaluated 492 asthma patients treated with ICS at two teaching hospitals. Patients were classified into early CR and non-early CR groups. Early CR was defined based on a composite set of criteria, including sustained absence of exacerbations, no systemic corticosteroid use, symptom control and stable or improved lung function in the first year following ICS initiation. Study outcomes were the annual forced expiratory volume in one second (FEV1) decline and the moderate-to-severe exacerbations. RESULTS: Early CR was significantly associated with slower annual FEV1 decline (4-component CR, adjusted β=31.6 mL/year, p=0.001; 3-component CR, adjusted β=15.7 mL/year, p=0.043). The benefits of early 4-component CR on attenuating annual FEV1 decline were more pronounced in specific phenotypes, including type-2 high asthma, persistent airflow limitation, severe asthma and patients requiring add-on long-acting muscarinic antagonists. Early 4-component CR had a reduced risk of moderate-to-severe (adjusted HR (aHR)=0.591, p=0.011) and severe exacerbations (aHR=0.508, p=0.025). CONCLUSIONS: Achieving CR within 1 year of ICS initiation was associated with improved lung function preservation and reduced exacerbation risk. These findings suggest the importance of achieving early CR as a clinical target in asthma management.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Bae, Park, Park, et al. Early clinical remission and its role in lung function decline and exacerbation in adult Korean patients with asthma. Thorax. 2025. PMID: 40050022. doi:10.1136/thorax-2024-222679

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。